Liver metastases in prostate carcinoma represent a relatively aggressive subtype refractory to hormonal therapy and short-duration response to docetaxel monotherapy

Arsh Singh, Naga K.S. Cheedella, Shams A. Shakil, Frederick Gulmi, Dong Sung Kim, Jen C. Wang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: We report a single institution's experience from a small series of patients suggesting that liver metastasis in metastatic castration-refractory prostate cancer (mCRPC) represents a relatively aggressive subtype that is refractory to hormonal manipulation treatment, including luteinizing hormone-releasing hormone agonist (LA) and abiraterone (Ab) therapy, although docetaxel is briefly effective. Methods: Between 2007 and 2013, six patients with prostate cancer with liver metastases were analyzed. Biochemical response was defined as > 50% decrease in prostate-specific antigen (PSA) value. Results: Two patients who presented with liver metastases died in less than 3 months after LA therapy. Two out of three patients (one died while receiving chemotherapy) received Ab after chemotherapy did not show any response and died while on therapy. One patient who presented with lung metastases initially received LA therapy and progressed on it with liver metastases in < 6 months. Thus, five of six patients did not respond to hormone therapy including LA and Ab. Three patients who received docetaxel after LA therapy had more than 50% objective PSA response with a mean survival of 4 months. Conclusions: No literature addresses the response to hormone treatment in hepatic metastasis in prostate carcinoma. This small series suggests that liver metastases in prostate carcinoma represent a relatively aggressive subset against which hormonal therapy, including the LA and Ab, appears to be ineffective. Although our patients responded to docetaxel chemotherapy, their responses were of short duration. A further clinical trial involving more patients will be necessary to substantiate our findings.

Original languageEnglish (US)
Pages (from-to)265-269
Number of pages5
JournalCJAM Canadian Journal of Addiction Medicine
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

docetaxel
Prostate
Neoplasm Metastasis
Carcinoma
Liver
Therapeutics
Prostate-Specific Antigen
Drug Therapy
Prostatic Neoplasms
Hormones
Castration
Liver Neoplasms

Keywords

  • Hepatic metastasis
  • Prostate carcinoma

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Liver metastases in prostate carcinoma represent a relatively aggressive subtype refractory to hormonal therapy and short-duration response to docetaxel monotherapy. / Singh, Arsh; Cheedella, Naga K.S.; Shakil, Shams A.; Gulmi, Frederick; Kim, Dong Sung; Wang, Jen C.

In: CJAM Canadian Journal of Addiction Medicine, Vol. 6, No. 1, 01.01.2015, p. 265-269.

Research output: Contribution to journalArticle

Singh, Arsh ; Cheedella, Naga K.S. ; Shakil, Shams A. ; Gulmi, Frederick ; Kim, Dong Sung ; Wang, Jen C. / Liver metastases in prostate carcinoma represent a relatively aggressive subtype refractory to hormonal therapy and short-duration response to docetaxel monotherapy. In: CJAM Canadian Journal of Addiction Medicine. 2015 ; Vol. 6, No. 1. pp. 265-269.
@article{28db63c0a91e444da27f616f697cf13c,
title = "Liver metastases in prostate carcinoma represent a relatively aggressive subtype refractory to hormonal therapy and short-duration response to docetaxel monotherapy",
abstract = "Background: We report a single institution's experience from a small series of patients suggesting that liver metastasis in metastatic castration-refractory prostate cancer (mCRPC) represents a relatively aggressive subtype that is refractory to hormonal manipulation treatment, including luteinizing hormone-releasing hormone agonist (LA) and abiraterone (Ab) therapy, although docetaxel is briefly effective. Methods: Between 2007 and 2013, six patients with prostate cancer with liver metastases were analyzed. Biochemical response was defined as > 50{\%} decrease in prostate-specific antigen (PSA) value. Results: Two patients who presented with liver metastases died in less than 3 months after LA therapy. Two out of three patients (one died while receiving chemotherapy) received Ab after chemotherapy did not show any response and died while on therapy. One patient who presented with lung metastases initially received LA therapy and progressed on it with liver metastases in < 6 months. Thus, five of six patients did not respond to hormone therapy including LA and Ab. Three patients who received docetaxel after LA therapy had more than 50{\%} objective PSA response with a mean survival of 4 months. Conclusions: No literature addresses the response to hormone treatment in hepatic metastasis in prostate carcinoma. This small series suggests that liver metastases in prostate carcinoma represent a relatively aggressive subset against which hormonal therapy, including the LA and Ab, appears to be ineffective. Although our patients responded to docetaxel chemotherapy, their responses were of short duration. A further clinical trial involving more patients will be necessary to substantiate our findings.",
keywords = "Hepatic metastasis, Prostate carcinoma",
author = "Arsh Singh and Cheedella, {Naga K.S.} and Shakil, {Shams A.} and Frederick Gulmi and Kim, {Dong Sung} and Wang, {Jen C.}",
year = "2015",
month = "1",
day = "1",
doi = "10.14740/wjon903w",
language = "English (US)",
volume = "6",
pages = "265--269",
journal = "CJAM Canadian Journal of Addiction Medicine",
issn = "1923-1210",
publisher = "Canadian Society of Addiction Medicine",
number = "1",

}

TY - JOUR

T1 - Liver metastases in prostate carcinoma represent a relatively aggressive subtype refractory to hormonal therapy and short-duration response to docetaxel monotherapy

AU - Singh, Arsh

AU - Cheedella, Naga K.S.

AU - Shakil, Shams A.

AU - Gulmi, Frederick

AU - Kim, Dong Sung

AU - Wang, Jen C.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: We report a single institution's experience from a small series of patients suggesting that liver metastasis in metastatic castration-refractory prostate cancer (mCRPC) represents a relatively aggressive subtype that is refractory to hormonal manipulation treatment, including luteinizing hormone-releasing hormone agonist (LA) and abiraterone (Ab) therapy, although docetaxel is briefly effective. Methods: Between 2007 and 2013, six patients with prostate cancer with liver metastases were analyzed. Biochemical response was defined as > 50% decrease in prostate-specific antigen (PSA) value. Results: Two patients who presented with liver metastases died in less than 3 months after LA therapy. Two out of three patients (one died while receiving chemotherapy) received Ab after chemotherapy did not show any response and died while on therapy. One patient who presented with lung metastases initially received LA therapy and progressed on it with liver metastases in < 6 months. Thus, five of six patients did not respond to hormone therapy including LA and Ab. Three patients who received docetaxel after LA therapy had more than 50% objective PSA response with a mean survival of 4 months. Conclusions: No literature addresses the response to hormone treatment in hepatic metastasis in prostate carcinoma. This small series suggests that liver metastases in prostate carcinoma represent a relatively aggressive subset against which hormonal therapy, including the LA and Ab, appears to be ineffective. Although our patients responded to docetaxel chemotherapy, their responses were of short duration. A further clinical trial involving more patients will be necessary to substantiate our findings.

AB - Background: We report a single institution's experience from a small series of patients suggesting that liver metastasis in metastatic castration-refractory prostate cancer (mCRPC) represents a relatively aggressive subtype that is refractory to hormonal manipulation treatment, including luteinizing hormone-releasing hormone agonist (LA) and abiraterone (Ab) therapy, although docetaxel is briefly effective. Methods: Between 2007 and 2013, six patients with prostate cancer with liver metastases were analyzed. Biochemical response was defined as > 50% decrease in prostate-specific antigen (PSA) value. Results: Two patients who presented with liver metastases died in less than 3 months after LA therapy. Two out of three patients (one died while receiving chemotherapy) received Ab after chemotherapy did not show any response and died while on therapy. One patient who presented with lung metastases initially received LA therapy and progressed on it with liver metastases in < 6 months. Thus, five of six patients did not respond to hormone therapy including LA and Ab. Three patients who received docetaxel after LA therapy had more than 50% objective PSA response with a mean survival of 4 months. Conclusions: No literature addresses the response to hormone treatment in hepatic metastasis in prostate carcinoma. This small series suggests that liver metastases in prostate carcinoma represent a relatively aggressive subset against which hormonal therapy, including the LA and Ab, appears to be ineffective. Although our patients responded to docetaxel chemotherapy, their responses were of short duration. A further clinical trial involving more patients will be necessary to substantiate our findings.

KW - Hepatic metastasis

KW - Prostate carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84928953055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928953055&partnerID=8YFLogxK

U2 - 10.14740/wjon903w

DO - 10.14740/wjon903w

M3 - Article

C2 - 29147414

AN - SCOPUS:84928953055

VL - 6

SP - 265

EP - 269

JO - CJAM Canadian Journal of Addiction Medicine

JF - CJAM Canadian Journal of Addiction Medicine

SN - 1923-1210

IS - 1

ER -